1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH search results confirm RFA-AI-22-028 is listed as 'Expired' and the stored deadline of 2025-02-28 aligns with the expiration. The URL returned 403 but the grant's expired status is confirmed via NIH search index.
Partnerships for Development of Innovative Therapeutics for Select Bacterial and Fungal Pathogens (R01) is sponsored by National Institutes of Health (NIAID). Encourages public-private partnerships to develop interventions against AMR pathogens. While therapy-focused, it supports genomic research to understand resistance mechanisms in global priority pathogens.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Universities, Nonprofits, and For-profit organizations. Confirm the full requirements in the official notice before applying.
The published deadline was February 28, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Partnerships for Development of Innovative Therapeutics for Select Bacterial and Fungal Pathogens (R01) is funded by National Institutes of Health (NIAID). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start with the full solicitation document linked on this page — it contains the submission instructions and required forms.
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) - PA-25-301 is sponsored by National Institutes of Health (NIAID). Supports investigator-initiated clinical research projects in areas including allergy, immunology, asthma, and infectious diseases. Foreign institutions are eligible to apply directly for most R01 mechanisms unless specifically excluded by the announcement.
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) - PA-25-304 is sponsored by National Institutes of Health (NIAID). Supports exploratory/developmental clinical research projects in allergy, immunology, and related fields. Foreign organizations eligible unless excluded; suitable for smaller-scale or pilot studies aligned with the organization's clinical research focus.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read article